Bavarian Nordic A/S (BVNRY) Fair Value & Analysis
Healthcare · US · Market cap $2.1B
Bavarian Nordic A/S
BVNRY · US
Fair value as of: Jul 15, 2026
From 24 valuation models · updated 10 days ago
Fair value updated Jul 15, 2026, revised from $19.27 to $18.75 (−2.7%) since Jun 24, 2026. Share price −2.1% over the past month.
Price vs Fair Value (12 months)
12‑month range $8.76 – $12.60 · fair‑value band $14.45 – $24.37 · the $8.76 price screens below the $18.75 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Bavarian Nordic A/S (BVNRY) currently trades at $8.76, while our model-based Fair Value estimate is $18.75, implying the stock looks roughly 114.0% undervalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Bavarian Nordic A/S generated revenue of $6.0B at a net margin of 19.7%. Revenue declined 21.4% year over year. It earns a return on equity of 9.7%. The balance sheet holds a net cash position of $1.6B. Fundamentals as of Jul 15, 2026
Our scenario range runs from $14.45 (bear case) to $24.37 (bull case); at $8.76, the current price sits below that range. The share trades about 33% below its 52-week high and 1% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -17% fair-value upside, at 114%, BVNRY screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bavarian Nordic A/S reported revenue of kr 5.9B in FY2025 versus kr 1.9B in FY2021, a compound +33.0%/yr. Reported net income was kr 1.3B in FY2025.
Is BVNRY fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$54.63 | R$46.79 | -14% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$123.32 | A$106.56 | -14% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$28.41 | R$23.67 | -17% |
| WuXi Biologics (Cayman) Inc 2269 | HK$30.74 | HK$28.99 | -6% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
| Genmab A/S GMAB | kr 1,704 | kr 209.21 | -88% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bavarian Nordic A/S (BVNRY) undervalued?
What is the fair value of BVNRY?
What is the quality score of BVNRY?
What is the revenue of Bavarian Nordic A/S (BVNRY)?
What is the net profit margin of BVNRY?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Bavarian Nordic A/S analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.